Federal Circuit denies rehearing in heart valve case

Judges will not rehear safe harbour case between Edwards and Meril | Medtech company said court’s precedent ‘distorts the market’ for patented products.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UPC confirms validity of Edwards Lifesciences heart valve tech patent

23 July 2024 Paris Central Division issues its first revocation judgment in dispute brought by Meril subsidiaries in Italy, Germany and India | Decision means infringement action by Edwards can resume at Munich Local Division | Damages worth €8m ($8.7m) | Gide, Marks & Clerk, Potter Clarkson among representatives.

Medtech

Judge tears into ‘safe harbour’ ruling in heart valve system case

26 March 2024 Judge’s dissenting opinion challenges the interpretation of the safe harbour provision by the US Court of Appeals for the Federal Circuit | Decision concerns Meril's importation of transcatheter heart valve systems in a dispute with Edwards Lifesciences | Court majority upheld the district court's ruling favouring Meril.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Federal Circuit denies rehearing in heart valve case

More on this story

Editor's picks

Editor's picks

More features